450 results on '"Frankel, Arthur"'
Search Results
2. The Psychodynamic Approach
3. The USGS 2023 Conterminous U.S. Time-Independent Earthquake Rupture Forecast
4. Unbiased Microbiome and Metabolomic Profiling of Fecal Samples from Patients with Melanoma
5. 3D Wave Propagation Simulations of Mw 6.5+ Earthquakes on the Tacoma Fault, Washington State, Considering the Effects of Topography, a Geotechnical Gradient, and a Fault Damage Zone
6. Genetically Engineered Toxins in Perspective
7. Supplementary Figures S1-S3 from Matrix Metalloproteinase–Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis
8. Supplementary Figures S1-S3 from Matrix Metalloproteinase–Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis
9. Supplementary Data from Matrix Metalloproteinase–Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis
10. Data from Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells
11. Data from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
12. Figure S1 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
13. Supplementary Fig. S4 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
14. Supplementary Fig. S1 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
15. Figure S2 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
16. Supplementary Fig. S1 from Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells
17. Supplementary Figure 2 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma
18. Supplementary Figure Legends from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
19. Figure S4 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
20. Supplementary Fig. S4 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
21. Supplementary Figure 1 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma
22. Supplementary Data Legends from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
23. Supplementary Fig. S1 from Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells
24. Data from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
25. Supplementary Fig. S2 from Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells
26. Data from Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells
27. Table S1 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
28. Supplementary Figure 1 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma
29. Tables S2-S9 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
30. Supplementary Fig. S2 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
31. Table S1 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
32. Supplementary Fig. S3 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
33. Figure S3 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
34. Supplementary Figure 2 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma
35. Supplementary Fig. S5 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
36. Supplementary Fig. S6 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
37. Supplementary Data Legends from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
38. Supplementary Table S1 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
39. Supplementary Fig. S1 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
40. Figure S1 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
41. Supplementary Fig. S6 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
42. Supplementary Figure Legends from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
43. Supplementary Fig. S3 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
44. Figure S2 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
45. Supplementary Fig. S2 from Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells
46. Figure S3 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
47. Supplementary Fig. S5 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
48. Supplementary Table S1 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
49. Figure S4 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
50. Supplementary Fig. S2 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.